Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

December 27, 2017 updated by: Boehringer Ingelheim

A Double-blind, Randomised Phase II Study to Determine Efficacy and Safety of Oral Treatment With BIBF 1120 ES 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Advanced Non-small-cell Lung Cancer

The overall purpose of this phase II trial was to evaluate the efficacy of 250 mg BIBF 1120 twice daily (BID) versus 150 mg BIBF 1120 BID in patients with advanced non-small-cell lung cancer (NSCLC) who had failed at least one prior chemotherapy regimen. In addition, safety data for the two different dosages were collected and analysed.

Study Overview

Study Type

Interventional

Enrollment (Actual)

73

Phase

  • Phase 2

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  1. Male or female patients with histologically confirmed advanced NSCLC (i.e. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, or combinations of these) stage IIIB (including pleural effusion) and stage IV.
  2. Patients with recurrent disease who relapsed after previous treatment with platinum- or non-platinum based chemotherapy.
  3. Full recovery from all therapy related toxicities from previous chemotherapy/ radiotherapy or recovery in as much as no further improvement may be expected by the investigator.
  4. Age ≥18 years.
  5. Life expectancy of at least 3 months.
  6. ECOG performance score 0, 1 or 2.
  7. Uni-dimensionally measurable tumour lesions by one or more techniques, i.e. CT, MRI, X-ray.
  8. Adequate hepatic function: total bilirubin within normal limits; alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 1.5x upper limit of normal (ULN) in patients without liver metastasis; For patients with liver metastasis: total bilirubin ≤ 1.5x ULN; ALT and/or AST < 2.5x ULN.
  9. Coagulation parameters: international normalised ratio less than 1.3 or prothrombin time (PT) and partial thromboplastin time (PTT) less than 1.5 times institutional ULN.
  10. Adequate renal function: serum creatinine ≤ 1.5 x upper normal limit.
  11. Absolute neutrophil count (ANC) ≥ 1500/mL, platelets ≥ 100000/mL, haemoglobin ≥ 9.0 g/dL.
  12. Written informed consent consistent with ICH-GCP guidelines and local law.

Exclusion criteria:

  1. Active brain metastases stable for < 4 weeks, symptomatic, or requiring treatment with anti-convulsants and/or steroids or leptomeningeal disease.
  2. Patients with history of haemorrhagic or thrombotic event (including transient ischemic attacks) in the past 12 months. Known inherited predisposition to thrombosis.
  3. Concurrent therapeutic anticoagulation (except heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except chronic low-dose daily acetylsalicylic acid < 325mg).
  4. Sanguineous pleural effusion due to disease or pericardial effusion suspicious for disease.
  5. Clinically significant haemoptysis (1 teaspoon or more) within the last 3 months.
  6. Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels.
  7. Radiographic evidence of cavitary or necrotic tumours at screening.
  8. Major injuries and surgeries. Planned surgical procedures during the trial. Patients with incomplete wound healing within the past 4 weeks.
  9. Gross haematuria within the last 3 months.
  10. Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of myocardial infarction within the past 6 months, serious cardiac arrhythmia, congestive heart failure according to New York Heart Association (NYHA) III or IV.
  11. Serious illness or concomitant non-oncological disease such as neurologic-, psychiatric- or infectious disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
  12. Gastrointestinal abnormalities that would interfere with intake or absorption of the study drug, prior surgical procedures affecting absorption, treatment for peptic ulcer disease within the last 6 months, active gastrointestinal bleeding unrelated to cancer (as evidenced by either hematemesis, hematochezia, or melena in the past 3 months and without endoscopic documented resolution), or malabsorption syndromes.
  13. Other malignancy within the past 5 years (other than non-melanomatous skin cancer or cervical carcinoma in situ).
  14. Treatment with other investigational drugs (elimination half life < 5 days) within the past 4 weeks before visit 2 or participation in another clinical trial within the past 4 weeks before start of therapy (visit 2) or concomitantly with this trial.
  15. Treatment with chemo-, immuno-, hormonotherapy or with biologic response modifier within the past four weeks prior to treatment with the trial drug and during the trial.
  16. Radiotherapy within the last 4 weeks prior start of treatment with the trial drug and radiotherapy to an area of measurable disease.
  17. Hypersensitivity to BIBF 1120 ES or the excipients of the trial drug.
  18. Male or female patients who are sexually active and unwilling to use a medically acceptable method of contraception prior to study entry and for the duration of study participation.
  19. Pregnancy or breast feeding.
  20. Known or suspected active alcohol or drug abuse.
  21. Patients unable to comply with the protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Experimental: BIBF 1120 ES low dose
Experimental: BIBF 1120 ES high dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Tumour response according to response evaluation criteria in solid tumours (RECIST)
Time Frame: baseline, every 6 weeks for an expected mean observation duration of 9 months
baseline, every 6 weeks for an expected mean observation duration of 9 months
Time to tumour progression
Time Frame: baseline, every 6 weeks for an expected mean observation duration of 9 months
baseline, every 6 weeks for an expected mean observation duration of 9 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall survival
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ) (EORTC QLQ-C30) score
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
EORTC QLC lung cancer module (QLQ-LC13) score
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
Incidence and intensity of adverse events, graded by Common Terminology Criteria (CTCAE) 3.0
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
Changes in safety laboratory parameters
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
Eastern Cooperative Oncology Group (ECOG) performance score
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
Changes in vital signs (body temperature, blood pressure, pulse rate, respiratory rate)
Time Frame: mean observation duration of 9 months
mean observation duration of 9 months
Maximum plasma concentration (Cmax)
Time Frame: pre-dose, 1, 2, and 3 hours after administration
pre-dose, 1, 2, and 3 hours after administration
Area under the curve (AUC)
Time Frame: pre-dose, 1, 2, and 3 hours after administration
pre-dose, 1, 2, and 3 hours after administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2005

Primary Completion (Actual)

January 1, 2007

Study Registration Dates

First Submitted

July 2, 2014

First Submitted That Met QC Criteria

July 7, 2014

First Posted (Estimate)

July 8, 2014

Study Record Updates

Last Update Posted (Actual)

December 28, 2017

Last Update Submitted That Met QC Criteria

December 27, 2017

Last Verified

December 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Clinical Trials on BIBF 1120 ES low dose

3
Subscribe